Posted from: Monday, August 01, 2016 - 01:20 PM - Present

Generic to Nilandron Tablets Announced

July 18, 2016 – The U.S. FDA approved ANI Pharmaceuticals’ A-rated generic to Concordia Pharms’ Nilandron® (nilutamide) 150mg tablets. Upon approval, ANI launched generic nilutamide tablets. Nilandron is an anti-androgen therapy indicated for use in combination with surgical castration for the treatment of patients with metastatic prostate cancer (Stage D2). The recommended dose is 300mg once daily for 30 days after which the dosage is 150mg once daily. 

 

Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.

Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval.  Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval.  Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only.  The reference to any medication above does not mean the medication is covered by your plan.

Last Updated Saturday, August 19, 2017 - 03:21 PM.